SCHEMBL4196833

SCHEMBL4196833

COc1ccc(N(Cc2cccnc2)c2ccc(C(=O)O)cc2)cc1OCc1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.46
AURKB Q96GD4 2/20 0.46
INCENP Q9NQS7 2/20 0.46
SMPD1 P17405 1/20 0.45
PDE4A P27815 3/20 0.44
PDE4B Q07343 3/20 0.44
PDE4C Q08493 3/20 0.44
PDE4D Q08499 3/20 0.44
ALDH1A1 P00352 4/20 0.44
NPSR1 Q6W5P4 2/20 0.44
HTT P42858 1/20 0.44
USP2 O75604 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 2/20 0.44
MAPT P10636 1/20 0.44
CSNK2A2 P19784 1/20 0.44
CSNK2A1 P68400 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.43
RXRA P19793 2/20 0.43
RAF1 P04049 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190538 0.88 ALDH1A1 (0.55) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4193526 0.88 L3MBTL1 (0.48) SMPD1PDE4APDE4BPDE4CPDE4D
SCHEMBL1157933 0.87 PDE4A (0.46) SYKPDE4APDE4BPDE4CPDE4D
SCHEMBL4196704 0.84 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL3129550 0.84 TSHR (0.52) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL1157397 0.84 RXRA (0.47) SMPD1PDE4APDE4BPDE4CPDE4D
SCHEMBL4191189 0.83 RXRA (0.49) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL1157792 0.83 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4188436 0.83 ALDH1A1 (0.47) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4190655 0.83 ALDH1A1 (0.50) PDE4APDE4BPDE4CPDE4DALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A SYK 3305/4885AURKB 3107/4885INCENP 3660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.